Last reviewed · How we verify

Ocusoft, Inc. — Portfolio Competitive Intelligence Brief

Ocusoft, Inc. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Retaine™ Retaine™ marketed Artificial tear / ocular lubricant Ophthalmology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Allergan · 1 shared drug class
  2. Chang Gung Memorial Hospital · 1 shared drug class
  3. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 1 shared drug class
  4. Medical University of Vienna · 1 shared drug class
  5. Nguyen Viet Giap · 1 shared drug class
  6. ORA, Inc. · 1 shared drug class
  7. The Mentholatum Company · 1 shared drug class
  8. Tianjin Eye Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Ocusoft, Inc.:

Cite this brief

Drug Landscape (2026). Ocusoft, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ocusoft-inc. Accessed 2026-05-13.

Related